News

Symposium Registration Now Open

Kathryn Arthy — 2015-07-20T05:00:00Z

Proudly sponsored by:

Registration is now open for the Prostate Cancer Collaborative Research 2015 Symposium to be held at the Translational Research Institute (TRI), Brisbane, Australia from Wednesday 25th to Saturday 28th November 2015.

The Prostate Cancer Collaborative Research Alliance was recently transformed from the Australian-Canadian Prostate Cancer Research Alliance (Aus-Can PCRA) that was founded in 2008. This Alliance currently has more than 285 clinical and scientific members from Australia, Canada & internationally. With the establishment of the Prostate Cancer Collaborative Research Alliance, all Aus-Can PCRA members have been transitioned to Prostate Cancer Collaborative Research Alliance membership.

Following the success of the four previous Aus-Can PCRA Symposia, the Prostate Cancer Collaborative Research 2015 Symposium will provide an excellent opportunity for prostate cancer clinicians, scientists, and other professionals to meet in a global context and share their research in a collaborative environment. Feedback from previous Aus-Can PCRA Symposia has consistently been very positive, with the event well-regarded as a nicely specialised meeting to generate and foster collaborations which differentiates it amongst the various international prostate cancer meetings.

The Prostate Cancer Collaborative Research 2015 Symposium will commence with a welcome reception on Wednesday afternoon 25th November and conclude mid-afternoon on Saturday 28th November. A preliminary program is available outlining draft topics for sessions which will feature short presentations focused on facilitating interactive discussions and opportunities to showcase research areas for collaboration.

PCCR 2015 Symposium registration is free for Prostate Cancer Collaborative Research Alliance members. If you are not a Prostate Cancer Collaborative Research Alliance member please register to join for free before submitting your PCCR 2015 Symposium registration.

Delegates will be responsible for their travel and accommodation costs to attend the PCCR 2015 Symposium.

Registration includes:

Entry to all Symposium sessions (Thursday – Saturday)
Access to the Symposium app (program, delegate profiles, etc)
Entry into the exhibition area and poster sessions (Thursday – Saturday)
Morning and Afternoon Teas and Lunch (Thursday – Saturday)
Attendance to the Welcome Reception (Wednesday 25 November)
Attendance to the Brisbane River Boat Cruise (Thursday 26 November)
Attendance to the Symposium Dinner (Friday 27 November)

REGISTER NOW

Please note that spaces are limited.

If you have any questions about the PCCR 2015 Symposium or the PCCR Alliance please contact us.

Dual successes for APCRC-Q PhD student, Claire Levrier

Kim Rasmussen — 2015-05-29T02:40:00Z

She won first prize for her oral presentation at the Australian Society for Medical Research (ASMR) Postgraduate Student Conference held at Queensland Institute of Medical Research (QIMR) on 27 May 2015.

Claire's presentation was entitled: "Mechanism of action studies in prostate cancer cells of a new compound isolated from an Australian endemic rainforest tree". The award included a cash prize of $300.

Claire was also awarded a CTx PhD top-up scholarship, worth $10,000 per annum for her research aimed at discovering new cytotoxic compounds from Australian endemic plants and their mechanisms of action in prostate cancer.

“These are very worthy achievements,” said APCRC-Q Executive Director and Claire’s co-supervisor, Prof Colleen Nelson. “Congratulations, Claire!”

Australian Prostate Cancer Bio Resource (APCB) receives funding from “It’s A Bloke Thing” Foundation and Prostate Cancer Foundation of Australia

Kim Rasmussen — 2015-04-02T02:35:00Z

The Australian Prostate Cancer Bio-Resource (APCB), led by APCRC-Q’s Scientific Director, Distinguished Professor Judith Clements, recently received a $200,000 contribution from the Prostate Cancer Foundation of Australia (PCFA) and the It's A Bloke Thing Foundation (IABTF).

These funds will assist the APCB as it underpins clinical trials and ongoing research nationally, and is involved in international consortia, such as the PRACTICAL prostate cancer genetic association study.

The biobank, which has four state nodes and is led from Queensland, has collected tissue samples from more than 5,500 men for the past 10 years and has 140,000 samples nationally and 40,000 in Queensland.

“It will be 10 years in October since we started collections and this is an extremely critical phase as we now need to gain more information on these men as to whether their disease has progressed or not. We are extremely grateful for the philanthropic support that comes to us through the Prostate Cancer Foundation of Australia, who has generously supported us for the past five years,” said Professor Clements, who has been working in prostate cancer research for the past 20 years.

"This funding will assist us in getting the critical information required for an integral part of the overall research into prostate cancer," she added.

PCFA national chairman, Mr Jim Hughes AM, said community support was vital for ongoing prostate cancer research.

"We have some wonderful community-based initiatives that help, like the Toowoomba-based It's A Bloke Thing (IABT) Foundation, which is responsible for half of this $200,000 donation," said Mr Hughes.

Started four years ago by a group a friends, including businessmen John Wagner, Gary Gardner, Mark Crampton and this year's chairman, John Fitzgibbons, the IABT lunch is Australia's most successful daytime fundraising event.

"We are extremely pleased that our event will help beneficiaries like the Australian Prostate Cancer Bio-Resource to continue their research programs," said Mr Fitzgibbons.

"Prostate cancer accounts for 30% of all cancers diagnosed in Australian men every year, and it is the second most common cause of cancer-related death, after lung cancer.”

"It's also not “just an old man's disease” so we need to reach men, particularly at a grassroots level and in rural communities."

APCRC-Q Researchers Receive NHMRC Development Grant Funding

Kim Rasmussen — 2015-03-28T02:30:00Z

The grant will assist with ground-breaking research into a new, more accurate test for prostate cancer, using technology developed by Minomic. This could lead to more accurate diagnosis and management of the disease.

Prostate cancer is the second most common cause of cancer-related death in Australian men, after lung cancer, accounting for about one-third of cancers diagnosed. One in five men over the age of 50 will be diagnosed with prostate cancer and each year 3,300 Australians die from the most aggressive forms of the disease.

This project, entitled: Novel prostate cancer target for diagnosis, imaging, detection of recurrence and response to therapy, will generate the critical new data for a novel, non-invasive test, developed by Minomic, and provide information concerning the potential of a new biomarker for imaging and treatment of late stage prostate cancer.

Professor Nelson, Executive Director of the APCRC-Q explains: "Our project aims to explore how this newly developed target can be better used for early detection, diagnosis, and monitoring of prostate cancer. We will also investigate the extent to which it can be used as both a new prostate cancer therapy and an imaging agent to monitor treatment and improve prostate cancer management with significant economic benefit to the healthcare system."

Chief Executive Officer of Minomic, Professor Walsh, said a recently completed 300 patient clinical study had shown "very promising results".

"Minomic is commercialising a non-invasive test that detects a protein found on prostate cancer cells, producing a more accurate diagnosis."

"The project will support further development of this novel biomarker in prostate cancer, which would bring significant benefit in terms of improving diagnosis, particularly of aggressive forms of the disease," he said.

If successful, the new test will require only a simple blood or urine sample, be quick, and non-invasive, and be performed in standard pathology labs. This means that patients who need treatment would receive it sooner, and those who don't would be spared the suffering and trauma of false positives.

The Development Grant forms part of $15.2 million in grants supporting the commercial development of products, processes and procedures which may result in positive health outcomes for Australians, announced by the National Health and Medical Research Council.

NHMRC CEO Professor Warwick Anderson explained the importance of these grants for translating research into positive health outcomes.

“Many of these grants are supported by leading Australian biotechnology companies which contribute intellectual property advice, salaries to support researchers, access to equipment and marketing expertise,” Professor Anderson said. “This collaboration is crucial to the translation of research and the creation of new industries in Australia.”

The full press release from NHMRC can be found here:
http://www.nhmrc.gov.au/media/releases/2015/new-grants-support-research-commercialisation

Professor Pamela Russell made a fellow of the Australian Academy of Health and Medical Sciences

Kim Rasmussen — 2015-03-27T02:25:00Z

Prof Russell’s current research focus is on discovering new methods for targeted imaging of prostate specific-membrane antigen (PSMA) expressed on prostate cancers, and developing theranostic agents, which can be used for magnetic resonance imaging (MRI) and positron emission tomography (PET). She is also part of a team performing PSMA-PET and functional MR imaging on patients with early prostate cancer.

“We congratulate Prof Russell on this outstanding achievement,” said Executive Director of the APCRC-Q, Prof Colleen Nelson, “Hers is an impressive career, peppered with well-deserved accolades in recognition of the numerous significant contributions she has made to the field.”

“It is a great honour to receive this award,” said Prof Russell. “I am very proud and pleased to be a part of the Academy and further its aims to promote academic medicine and translational health and medical sciences in Australia, and contribute to the development of future generations of health and medical researchers.”

Current research projects in which Prof Russell is involved include research into new biomarkers in vesicles, known as exosomes, which may predict the response of castration-resistant prostate cancer (CRPC) to chemotherapy.

Prof Russell is a co-recipient, with Prof Nelson, of an NHMRC Development grant to study diagnosis imaging and therapy of prostate cancer. In addition to funding from the NHMRC, Prof Russell is part of the Movember Global Action Plan program, and a member of the APCRC-Q’s Movember Revolutionary Team Award, led by Prof Nelson. She also serves on the Movember Global Action Plan scientific and research advisory committees.

A co-founder of the Genitourinary Oncology Group Australasia, Professor Russell also contributed to the establishment of the PCFA of which she was an inaugural director and now holds life membership. Prof Russell was honoured by the PCFA for her tireless work in prostate cancer by being named the PCFA Cancer Researcher of the Year in 2010.

In 2009, she was made a life member of the Australasian Gene Therapy Society, and received the prize for outstanding research alumnus of Sydney's Kolling Institute of Medical Research in 2006.

In 2003, her research on bladder and prostate cancer saw her awarded membership of the Order of Australia.

She was Professor of Medicine, University of New South Wales (UNSW), and director of the Oncology Research Centre at the UNSW School of Medicine at Prince of Wales Hospital from 1992 to 2008.

She has been awarded more than $37 million in research grants and has published more than 200 peer-reviewed journal articles, as well as several reviews and book chapters.

QUT is offering 2 research capacity building 5 year professorial appointments in Cancer Biology and Molecular Medicine

Kim Rasmussen — 2015-01-15T06:41:01Z

QUT invites applications from high profile outstanding researchers, especially those with complementary interests to our current prostate, breast, ovarian, endometrial and lung cancer strengths.

Application details for the 2 positions are available from:

APCRC-Q MO-mentous MOvember

Kim Rasmussen — 2014-11-11T05:54:17Z

In keeping with this year’s ‘Made In Movember’ theme, the Morning Tea Stall at the Team Launch was a huge success with an amazing selection of home-made savoury and sweet delicacies sold at the Translational Research Institute and Princess Alexandra Hospital.

More fundraising events are planned with a Cupcake Stall on Wednesday 12 November and a Wine Tasting on Thursday 27 November. Please support the APCRC-Q Mo Bros and Mo Sistas by donating now!

As the proud beneficiary of over $8 million of funds raised by Movember, APCRC-Q is also spreading the word about its research and raising awareness of prostate cancer throughout Queensland. Dr Brett Hollier and Dr Rohan Davis are travelling to Rockhampton later this month as invited guests of the Rockhampton Prostate Cancer Support Group.

Sizzling Support for PCFA’s Big Aussie Barbie

Kim Rasmussen — 2014-09-29T06:00:00Z

Now in its fifth year, the campaign aims to raise over $1 million and promote community awareness of prostate cancer.

APCRC-Q researchers donned aprons and tongs to host a barbeque at QUT’s Institute of Health and Biomedical Innovation on Friday 26 September. As the beneficiary of funding from PCFA, the Centre is pleased to contribute to this campaign. With generous support from local businesses, APCRC-Q donated over $900.

Translational Research Institute To Appoint New Chief Executive Officer

Kathryn Arthy — 2014-03-26T03:05:00Z

Prof Ian Frazer will conclude his three year tenure as CEO and Director of Research of Translational Research Institute (TRI) on 30 June 2014. He will continue to support the development of the TRI as an Ambassador for its new fundraising Board.

TRI is now progressing the appointment of a CEO and Director of Research. Download the CEO Prospectus from the TRI website. Initial enquiries should be directed in confidence to: Dr Rachel Lucas, RLC Search on +61 (0)402 891 029 or rachel@rlcsearch.com

Photos courtesy of Translational Research Institute

APCRC-Q leads a Revolutionary Team Award

Kathryn Arthy — 2014-03-17T06:49:55Z

Funded by The Movember Foundation, this Revolutionary Team Award will extend APCRC-Q’s national and international collaborations. With investigators from seven Australian research institutions in Brisbane, Sydney, Melbourne, and Adelaide, in addition to researchers in Canada, Ireland and the USA, the trans-disciplinary team will investigate treatment resistance to the largest class of inhibitors currently used to treat prostate cancer (Androgen Targeted Therapies or ATT).

Professor Colleen Nelson, APCRC-Q’s Executive Director and Leader of the Movember Revolutionary Team said “Our Team’s ultimate goal is to determine adaptive pathways inadvertently activated by ATT which can be targeted to strategically be used in combination or in sequence with ATTs to improve outcomes in advanced prostate cancer”.

The team will be closely engaged with the other Australian Movember Revolutionary Team based from Sydney, who are studying prostate cancer cell dormancy in metastatic disease.

“I’m delighted that this collaborative programme recognises the significant benefits of sharing expertise and data across a trans-disciplinary team focused on a common goal. We are looking forward to improving clinical treatment options and outcomes for advanced prostate cancer patients” Professor Nelson said.

APCRC-Q supporting Movember

Kim Rasmussen — 2013-11-27T03:10:59Z

With 26 Mo Bros and Mo Sistas on board, APCRC-Q's Movember Team is committed to changing the face of men's health.

Our researchers have filmed a video to thank everyone growing a Mo this year:

Cup Cake sale and Mo Check in

Wine Tasting Fundraiser

Mo Judging

Our friends in Princess Alexandra Hospital's Pathology Department had great fun dressing up as Mo Bros and generously donated their fundraising proceeds to our team.

Mourning the Mo

On Friday 29th Movember we will be holding our last fundraising event to celebrate the month of Movember with a morning tea and judging of APCRC-Q's 2013 Mo King & Mo Raiser. Will these previous winners claim another prize this year?

Dr Stephen McPherson - Mo King 2011

Dr Varinder Jeet - Mo King 2012

Dr Brett Hollier - Mo Raiser 2012

Collaboration results in ground-breaking discovery

Kim Rasmussen — 2013-09-24T06:54:13Z

APCRC-Q researchers Dr Melanie Lehman and Prof Colleen Nelson teamed up with researchers from Sydney, Vancouver, Adelaide, and Brisbane in a collaboration which began through the Australian-Canadian Prostate Cancer Research Alliance and resulted in a ground-breaking discovery, which has brought scientists closer to a new treatment for prostate cancer that relies on starving tumours of essential nutrients they need to grow.

In a recently published article in JNCI, lead investigators Dr Qian Wang and Dr Jeff Holst, both of the Origins of Cancer Laboratory, Centenary Institute, Sydney and their collaborators demonstrate that they can slow the growth of the cancer by blocking the proteins which pump the amino acid leucine into tumour cells.

A JNCI editorial on the article by Dr Andrew Tee from Cardiff University describes this work as “a landmark article that uncovers the Achilles heel of prostate cancer,” and goes on to say that “Discovery of this leucine hunger in metastatic prostate cancer opens up a new therapeutic option to treat prostate cancer by inhibiting amino acid transporters.”

Leucine is not only used to construct proteins within cells, but it also stimulates cell division—and overactive cell division causes cancer. However, leucine cannot be produced within the body, making it an essential nutrient which must come from the diet and be transported into cells by specialised protein pumps.

In 2011, the team demonstrated that prostate cancer cells have more pumps on their surface than ordinary cells, which allows the cancer cells to take in more leucine and outgrow normal cells.

In the new study, researchers blocked the leucine pumps with chemicals, which resulted in inhibition of the activity of more than 100 genes responsible for prostate cancer growth and spread.

“There are currently no drugs that target these nutrient pumps,” Dr Holst says, “but we are working on that. We are confident we will have new compounds available for testing in the clinic in the next few years.”

Prof Colleen Nelson said: “The work is particularly good news for men suffering from prostate cancers that have become resistant to standard treatments, such as Androgen deprivation therapy (lowering the levels of exposure to male sex hormones).”

The team’s work was supported by the Prostate Cancer Foundation of Australia, Movember, National Breast Cancer Foundation, Cancer Institute NSW, Ramaciotti Foundation, Rebecca L. Cooper Medical Research Foundation, Tour de Cure, Cancer Australia, Cure the Future, anonymous foundation, National Health & Medical Research Council; and the Australian-Canadian Prostate Cancer Research Alliance.

For interviews contact

Jeff Holst +61 401 081 974 or +61 2 9565 6172

Background information

About Prostate cancer

Prostate cancer is the most common cancer in Australian men and is the second most common cause of cancer deaths in men (after lung cancer). Generally at the early and potentially curable stage, prostate cancer does not have obvious symptoms. This makes it different from other benign prostate disorders, which may result in urinary symptoms. Men aged 50 and over should talk to their doctor about prostate cancer and if they decide to be tested, to do so annually. If there is a family history of prostate cancer; men should talk to their doctor from the age of 40.

Source: Prostate Cancer Foundation of Australia

For more on prostate cancer diagnosis, treatment and support refer to the Prostate Cancer Foundation of Australia

About the Australian Prostate Cancer Research Centre-Queensland

The Australian Prostate Cancer Research Centre-Queensland (APCRC-Q) is one of two nationally-funded centres of excellence in prostate cancer research. Members of the APCRC-Q comprise a large, coordinated multidisciplinary research team who seamlessly span the discovery, therapeutic and diagnostic development spectrum of prostate cancer.

Researchers within the Centre have expertise in gene expression, regulation, animal models, imaging, steroid hormones, molecular endocrinology and targeted therapeutics.

With a strong focus on the development of new therapeutics and predictive biomarkers for prostate cancer, via a collaborative, trans-disciplinary and translational approach, the APCRC-Q objectives are to:

Develop, evaluate, and validate novel biomarkers for patient risk profile stratification.
Accelerate discovery and pre-clinical development of anti-cancer therapeutics.
Clinically evaluate novel therapeutics in Phase I, II and III trials within a multidisciplinary prostate uro-oncology clinical trials centre.
Improve management of prostate cancer patients in Australia through implementing the latest approved advances in prostate cancer treatments.

Citation

Targeting Amino Acid Transport in Metastatic Castration-Resistant Prostate Cancer: Effects on Cell Cycle, Cell Growth, and Tumor Development

Qian Wang, Jessamy Tiffen, Charles G. Bailey, Melanie L. Lehman, William Ritchie, Ladan Fazli, Cynthia Metierre, Yue (Julie) Feng, Estelle Li, Martin Gleave, Grant Buchanan, Colleen C. Nelson, John E. J. Rasko and Jeff Holst

Affiliations of authors: Origins of Cancer Laboratory (QW, JT, JH) and Gene & Stem Cell Therapy Program (QW, JT, CGB, WR, CM, YF, JEJR, JH), Centenary Institute, Camperdown, Australia; Sydney Medical School, University of Sydney, Sydney, Australia (QW, JT, CGB, WR, CM, YF, JEJR, JH); Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada (MLL, LF, EL, MG, CCN); Cancer Biology Group, Basil Hetzel Institute for Translational Health Research, University of Adelaide, Adelaide, Australia (GB); Australian Prostate Cancer Research Centre-Queensland, Queensland University of Technology, Brisbane, Australia (CCN, MLL); Cell and Molecular Therapies, Royal Prince Alfred Hospital, Camperdown, Australia (JEJR).

Correspondence to

Jeff Holst j.holst@centenary.org.au or
Origins of Cancer Laboratory, Locked Bag 6, Newtown, NSW 2042 Australia

Australian Prostate Cancer Research Centre - Queensland receives $6.2m funding from the Australian Government

Kim Rasmussen — 2013-05-22T04:31:39Z

The recent Federal Budget included funding of $18.5 million over four years to expand the Australian Prostate Cancer Research Centres initiative. The APCRC-Q and the Australian Prostate Cancer Research Centre - Victoria will be extended and receive $6.2 million each. A new Australian Prostate Cancer Research Centre will be established at the Kinghorn Cancer Centre in Sydney with an allocation of $5.5 million.

APCRC-Q Executive Director Professor Colleen Nelson said “In 2009 the Government established an unparalleled opportunity with this dedicated prostate cancer health initiative to bring together urologists, oncologists, radiologists, pathologists, biomedical scientists and health economists to work in a team-based environment to translate discoveries into clinical impact.

The synergies created in linking the latest research findings and clinical care will greatly improve the management and outcomes of prostate cancer patients in Australia. We are delighted that this model of research has been recognised and will be built upon with further collaborative efforts across the Australian Prostate Cancer Research Centres and throughout the larger prostate cancer research community.”

Professor Judith Clements, APCRC-Q’s Scientific Director said “This funding renewal builds on the initial outcomes of our first five years and recognises the importance of researchers being embedded within a clinical environment to facilitate research into the most important clinically relevant questions. The recent consolidation of our laboratories into the new Translational Research Institute on the Princess Alexandra Hospital campus further strengthens our translational capabilities.”

Working together towards a better future for prostate cancer patients

The APCRC-Q is a joint initiative between Queensland University of Technology's Institute of Health and Biomedical Innovation and the Princess Alexandra Hospital.

The APCRC-Q’s strength lies in its integrated, trans-disciplinary approach that spans the full spectrum of prostate cancer disease from the development of prostate cancer therapeutics and biomarkers, through to therapeutic response indicators to inform treatment options, and the evaluation of health services and health economics of delivering improved treatments to prostate cancer patients.

Professor Ross Young, QUT’s Faculty of Health Executive Dean said “Our commitment to furthering collaboration between scientists and clinicians in improving the diagnosis and treatment of prostate cancer is a crucial advance for men’s health. We applaud the Australian Government’s investment in this internationally significant body of work. The outcomes of this research will be of global significance in terms of future improvements in health and the generation of expertise and new drug therapies.”

The APCRC-Q is dedicated to the translation of prostate cancer research from bench to bedside, with a strong emphasis on developing national and international collaborations. The Centre brings together a hospital and an academic institution and is a leading example of multi-disciplinary effort within a national research network. This operational model is strongly aligned with the recommendations of the McKeon review of national health and medical research. The APCRC-Q is pleased to be at the forefront of championing and delivering this model of research to make clinical impact. The Centre is closely integrated with the Princess Alexandra Hospital, the Translational Research Institute and Diamantina Health Partners.

Professor David Theile, Chair of Diamantina Health Partners said “The approach of APCRC-Q which fully integrates scientific research with multidisciplinary practical care of patients gives great advantages in the fight against this very common cancer but also serves as an exemplary model in the bid to control diseases. This is strongly supported by Diamantina Health Partners.”

A multi-disciplinary team addresses the many facets of the disease

APCRC-Q used the initial $7.5m funding from the Australian Government to establish its large, coordinated multidisciplinary research team who will use the additional $6.2 million funding to improve diagnostic tests and treatments and their delivery for men with advanced prostate cancer.

Prostate Cancer Canada announces Travel Awards for 2013 Aus-CanPCRA Symposium

Kathryn Arthy — 2013-05-01T01:01:06Z

PCC will provide a $1,000 contribution to travel costs to 15 researchers attending the meeting. This award is intended to support researchers at all stages of their career including but not limited to Principal Investigators, postdoctoral fellows, students and technical staff. This symposium has proven to be a good venue to develop and establish collaborations among researchers and this forms the rationale behind this current opportunity provided by PCC.

Applications will be subject to a peer review process to identify the most meritorious applicants. Applications will be reviewed and awards made based on the following criteria:

• Significance and relevance of prostate cancer research being presented

• Proposed plan to develop new collaborations and expand networking

Applicants for the PCC Aus-CanPCRA Travel Award must meet the following expectations:

1. Join the Aus-CanPCRA online if not already a member. Membership is free and can be done by visiting the Aus-CanPCRA website at: http://www.aus-canprostatealliance.org/about-us/become-a-member

2. Submit an abstract and be prepared to present their science/expertise/resources through a talk, abstract and/or poster at the symposium.

3. State their collaborative goals for attending the symposium. Preference will be given to applicants who can outline their plan for contributing to the development of new collaborative connections and for networking with other delegates.

4. Attend the entire symposium.

5. Provide a report to the PCC after the symposium on the collaborative relationships established.

Timeline

Application Deadline: Friday, May 24, 2013 at 5:00 PM EDT

Results Announced: Wednesday, June 5, 2013

Apply Now!

Apply online at http://fluidsurveys.com/surveys/pcc/research-travel-awards-program/

Please visit the 2013 Aus-CanPCRA Symposium page for further information about the Symposium.

US Department of Defense Pre-Announcement for Prostate Cancer Research Program

Kathryn Arthy — 2013-04-18T08:04:43Z

The focus areas for the program are: 1) Biomarker Development; 2) Genetics; 3) Imaging; 4) Mechanisms of Resistance; 5) Survivorship and Palliative Care; 6) Therapy; and 7) Tumor and Microenvironment Biology.

It is anticipated that Program Announcements and General Application Instructions for the 13 awards will be posted on the grants.gov website in May and June 2013.

Further information is available at: http://cdmrp.army.mil/pubs/press/2013/13pcrppreann.shtml